secwatch / observer
8-K filed July 7, 2023, 7:59 PM ET CIK 0001497504
leadership confidence high sentiment negative materiality 0.60

PLx Pharma Winddown terminates CEO and CFO amid Chapter 11 proceedings

PLx Pharma Winddown Corp.

item 5.02item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Natasha Giordano

President and Chief Executive Officer
PLx Pharma Winddown Corp.
Effective
2023-06-30
Filed
July 7, 2023, 7:59 PM ET
In connection with the Chapter 11 Cases, on June 30, 2023, the Company terminated the employment of Natasha Giordano, President and Chief Executive Officer, and of Rita O’Connor, Chief Financial Officer and Head of Manufacturing and Supply Chain.
Departed

Rita O’Connor

Chief Financial Officer and Head of Manufacturing and Supply Chain
PLx Pharma Winddown Corp.
Effective
2023-06-30
Filed
July 7, 2023, 7:59 PM ET
In connection with the Chapter 11 Cases, on June 30, 2023, the Company terminated the employment of Natasha Giordano, President and Chief Executive Officer, and of Rita O’Connor, Chief Financial Officer and Head of Manufacturing and Supply Chain.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Natasha Giordano was terminated as President and Chief Executive Officer at PLx Pharma Winddown Corp..

Action
terminated
Role
President and Chief Executive Officer
Exact text from the filing
In connection with the Chapter 11 Cases, on June 30, 2023, the Company terminated the employment of Natasha Giordano, President and Chief Executive Officer, and of Rita O’Connor, Chief Financial Officer and Head of Manufacturing and Supply Chain.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Rita O’Connor was terminated as Chief Financial Officer and Head of Manufacturing and Supply Chain at PLx Pharma Winddown Corp..

Action
terminated
Role
Chief Financial Officer and Head of Manufacturing and Supply Chain
Exact text from the filing
In connection with the Chapter 11 Cases, on June 30, 2023, the Company terminated the employment of Natasha Giordano, President and Chief Executive Officer, and of Rita O’Connor, Chief Financial Officer and Head of Manufacturing and Supply Chain.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PLx Pharma Winddown Corp.: Amended Article 6 of the Bylaws to clarify officer requirements and make other clarifying changes (effective 2023-07-07).

Change
bylaw amendment
Effective
2023-07-07
Exact text from the filing
On July 7, 2023, the Board of Directors of the Company approved, and adopted effective as of such date, an amendment (the “Amendment”) to its Amended and Restated Bylaws (the “Bylaws”). The Amendment amends Article 6 of the Bylaws to clarify the requirements regarding officers of the Company and to make certain other clarifying changes.
View on SEC.gov

27 governance changes filed in the last 30 days. Browse all governance changes →

Source: SEC EDGAR
accession 0001193805-23-000963
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.